FdaApplication
BLA 761417
Identifiers
- fda_app_no: BLA761417
Properties
| Property | Value |
|---|---|
| applicant_name | BEIGENE |
| application_type | BLA |
Revenue by product
TEVIMBRA
| Period | Revenue |
|---|---|
| Q2 2026 | $228.5M |
| Q2 2025 | $193.5M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| TEVIMBRA | TISLELIZUMAB-JSGR | 100MG/10ML(10MG/ML) | INJECTABLE;INTRAVENOUS |
1 product